Please check your internet connection and try again.
# Pantoprazole
## Overview
Pantoprazole is a proton pump inhibitor (PPI) that suppresses gastric acid secretion.
## Primary Indications
* Healing of erosive esophagitis associated with gastroesophageal reflux disease (GERD).
* Maintenance of healing of erosive esophagitis.
* Pathological hypersecretory conditions, including Zollinger-Ellison syndrome (ZES).
## Adult Dosing
* **Erosive Esophagitis:** 40 mg orally or intravenously once daily for up to 8 weeks. For maintenance of healing, 40 mg orally once daily.
* **Zollinger-Ellison Syndrome:** 40 mg orally or intravenously twice daily, may be increased to 80 mg intravenously or orally once daily or divided into twice daily doses. Doses should be adjusted based on individual patient response. Maximum dose: 160 mg daily.
## Pediatric Dosing
* **Erosive Esophagitis (12 years and older):** 40 mg orally once daily for up to 8 weeks.
* **GERD (5 years and older):** 20 mg to 40 mg orally once daily. Dosing depends on weight and indication.
* **Note:** Efficacy and safety for other indications in pediatric patients have not been established. Specific dosing often depends on local protocols and patient factors.
## Dose Adjustments
No dose adjustment is typically required for hepatic or renal impairment, although caution may be advised in severe hepatic impairment.
## Contraindications
* Known hypersensitivity to pantoprazole or any component of the formulation.
## Adverse Effects
Common: Headache, diarrhea, nausea, abdominal pain, flatulence, dizziness.
Serious: Fundic gland polyps (long-term use), *Clostridium difficile*-associated diarrhea, bone fracture (hip, wrist, spine) with prolonged high-dose use, hypomagnesemia (can be severe and prolonged), vitamin B12 deficiency.
## Key Drug Interactions
* **Drugs requiring gastric acid for absorption:** Ketoconazole, itraconazole, posaconazole, iron salts, vitamin B12. Pantoprazole can decrease absorption.
* **Methotrexate:** PPIs may increase methotrexate levels, potentially leading to toxicity.
* **CYP2C19 substrates:** Pantoprazole can inhibit CYP2C19, potentially affecting the metabolism of drugs like clopidogrel, although the clinical significance with pantoprazole is debated and generally considered less than with omeprazole.
## Monitoring
* Monitor for signs and symptoms of hypomagnesemia (e.g., muscle cramps, seizures, arrhythmias).
* Consider monitoring vitamin B12 levels with prolonged therapy.
* Monitor for *Clostridium difficile* infection if diarrhea occurs.
* For ZES, monitor gastric pH and clinical symptoms.
## Clinical Pearls
* Administer oral pantoprazole 30 minutes before a meal.
* IV infusion should be administered over at least 15 minutes.
* Long-term use of PPIs is associated with potential risks, including fractures, *C. difficile* infection, and hypomagnesemia. Use the lowest effective dose for the shortest duration necessary.
***
**Disclaimer:** This information is intended for clinical decision support and does not replace a thorough review of the most current prescribing information, institutional protocols, and patient-specific factors. Always verify the latest drug information before use.
